Otsuka Holdings Co., Ltd.(4578) News

Otsuka Receives FDA Accelerated Approval for VOYXACT(sibeprenlimab-szsi)

Sibeprenlimab Phase 3 Data Presented at American Society of Nephrology Kidney Week 2025

Consolidated Financial Results for the Nine-Month Period Ended September 30, 2025 [IFRS]

Otsuka, Jan-Sep (Cumulative 3Q) Net Income Increases by 55%, Jul-Sep Net Income Increases by 48%

Integrated Report 2025

(Progress of Disclosure)Notice of Completion of Share Transfer of Equity-Method Affiliate

Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI

Notice Regarding Partial Amendment to “Notification of Change of Equity Method Affiliate (Transfer of Shares)”

Notice of Payment of Interim Dividend and Revision of Annual Dividend Forecast

Otsuka, Net Income Forecast for the Fiscal Year Revised Upward by 20%, Dividend Revised Upward by 20 Yen

Consolidated Financial Results for the Six-Month Period Ended June 30, 2025 [IFRS]

Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2025

Otsuka, Net Income Forecast for First Half Revised Upward by 18%

Notification of Change of Equity Method Affiliate (Transfer of Shares)

Otsuka and Lundbeck Issue Statement on U.S. FDA Advisory Committee Meeting on REXULTI for the Treatment of Adults with PTSD

Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of IgAN

Otsuka Announces FDA Acceptance and Priority Review of BLA for Sibeprenlimab in the Treatment of IgAN

Notice Regarding Change in Major Shareholders

Consolidated Financial Results for the Three-Month Period Ended March 31, 2025 [IFRS]

Otsuka, Jan-Mar (1Q) Net Income Increases by 10%